CEL-SCI study in Oral Oncology flags low PD-L1, N0 oral cancer patients for Multikine survival benefitPUBT·Aug 4 at 07:02 AMCVM+0.65%
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | CVM Stock NewsStockTitan·Jul 29 at 11:31 PMCVM+0.65%
CEL-SCI notifies availability of Multikine Phase 3 confirmatory study launch releasePUBT·Jul 13 at 07:01 AMCVM+0.65%
CEL-SCI signs agreement with Saudi Amarox to support Multikine commercialization in Saudi ArabiaPUBT·Jun 24 at 07:01 AMCVM+0.65%
CEL-SCI Completes $2.5M Stock Offering at $1.00, Engages ThinkEquity as Placement AgentTradingView·Jun 16 at 04:13 PMCVM+0.65%
